Replies to post #129245 on Biotech Values

[DewDiligence]

The problem with this argument is that Amphastar undoubtedly already included in its calculations the strong probability of an authorized generic immediately after it launched.

That’s why I labeled the argument somewhat illogical; however, I think it makes as much sense as the alternate rationale concerning stocking the channel.